-
公开(公告)号：KR1020010065950A
公开(公告)日：2001-07-11
申请号：KR1019990067521
申请日：1999-12-30
Applicant: 일양약품주식회사
IPC: C07D401/14
Abstract: PURPOSE: Provided is a method of separating (-)-enantiomer of the title compound which has better effect of inhibiting excretion of the gastric acid and cell protecting anti-ulcer activity. CONSTITUTION: The title compound is 2-££(4-methoxy-3-methyl)-2-pyridinyl|methylsulfinyl|-5-(1H-pyrrole-1-yl)-1H-benzimidazole represented by the compound (1) from which (-)-enantiomer is separated. The separation process comprises dissolving the racemate in methanol and filtering through membrane filter and separating the enantiomer from the filtrate by column chromatography using Amylose-based solid phase column.
Abstract translation: 目的：提供标题化合物的（ - ） - 对映异构体分离方法，其具有抑制胃酸排泄和细胞保护抗溃疡活性的更好效果。 构成：由化合物（1）表示的标题化合物是2-（4-甲氧基-3-甲基）-2-吡啶基|甲基亚磺酰基| -5-（1H-吡咯-1-基）-1H-苯并咪唑，由 分离出（ - ） - 对映异构体。 分离过程包括将外消旋体溶解在甲醇中并通过膜过滤器过滤并通过使用直链淀粉基固相柱的柱色谱法从滤液中分离对映异构体。
-
公开(公告)号：KR100299562B1
公开(公告)日：2001-11-22
申请号：KR1019980060261
申请日：1998-12-29
Applicant: 일양약품주식회사
IPC: A61K31/415 , A61K31/44
Abstract: 본 발명은 항궤양제로서 매우 유용하지만 산에는 극히 불안정한 하기 화학식 1의 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체의 안정화제로서 알칼리 화합물을 사용하고 수용성 고분자를 결합제로 사용하여 제조된 미세과립에 관한 것이다:
상기식에서
X, R
1 , R
2 , R
3 , R
4 및 R
5 는 명세서에서 정의한 바와 같다.-
Patent Agency Ranking3.发明授权
-
4.发明授权항산화, 미백, 보습, 면역증강 및 항여드름 작용을 나타내는 목질진흙버섯 자실체 및 배양균사체 추출물, 그 제조방법 및 용도 失效具有抗氧化增白保湿免疫增强和抗痤疮活性的桑黄提取物的制备方法及用途
公开(公告)号：KR100320743B1
公开(公告)日：2002-01-19
申请号：KR1019990007092
申请日：1999-03-04
Applicant: 일양약품주식회사
Abstract: 본발명은목질진흙버섯(, 桑黃)의자실체또는액체배양에의해수득된목질진흙버섯의균사체배양물을열수추출한후분리정제하여수득되는, 항산화, 미백, 보습, 면역증강및 항여드름작용등을나타내는목질진흙버섯추출물, 그의제조방법및 화장료또는식품으로서의그의용도에관한것이다.
-
公开(公告)号：KR1020000059470A
公开(公告)日：2000-10-05
申请号：KR1019990007092
申请日：1999-03-04
Applicant: 일양약품주식회사
Abstract: PURPOSE: Extract of Phellinus liteus and a preparing method thereof are provided. The extract has anti-oxidation effect, whitening effect and moisture retentive effect and anti-acne effect and it improves immunity. Therefore, The extract is used for cosmetics and foods. CONSTITUTION: Extracts of Phellinus liteus are obtained by extraction, separation and purification of fruit bodies or hyphae obtained from liquid cultivation. The liquid medium, which is used for cultivating hyphae of Phellinus liteus, comprises 0.1-5% of glucose, 0.05-3% of yeast extract, 0.05-3% of peptone, 0.05% of MgSO4, 0.046% of KH2PO4, 0.01% of CaHPO4, 0.01% of FeCl3.6H2O as trace elements, 0.0072% of MnCl2.4H2O, 0.0025% of CuSO4.5H2O and 0.004% of ZnCl2. The hyphae of Phellinus liteus is cultivated in the liquid medium at 25-35°C for 3-10 days. Then, the hyphae is hot water-extracted by adding purified water thereto, followed by being filtrated and recovered.
Abstract translation: 目的：提供枸杞提取物及其制备方法。 提取物具有抗氧化作用，美白效果和保湿效果和抗痤疮效果，提高了免疫力。 因此，提取物用于化妆品和食品。 构成：通过提取，分离和纯化从液体培养获得的果实或菌丝获得桑黄提取物。 用于培养枸杞的菌丝的液体培养基包含0.1-5％的葡萄糖，0.05-3％的酵母提取物，0.05-3％的蛋白胨，0.05％的MgSO 4，0.046％的KH 2 PO 4，0.01％的 CaHPO 4，0.01％FeCl 3·6H 2 O作为微量元素，0.0072％MnCl 2·4H 2 O，0.0025％CuSO 4·5H 2 O和0.004％ZnCl 2。 在25-35℃下，在液体培养基中培养桑黄的菌丝3-10天。 然后，通过向其中加入纯水将菌丝热水提取，然后过滤并回收。
-
公开(公告)号：KR1020000043837A
公开(公告)日：2000-07-15
申请号：KR1019980060261
申请日：1998-12-29
Applicant: 일양약품주식회사
IPC: A61K31/415 , A61K31/44
CPC classification number: A61K9/1652 , A61K31/4439 , A61K47/02
Abstract: PURPOSE: A microgranule containing stabilized 5-pirrolyl-2-pyridylmethylsulfinylbenzimidazole derivative (formula 1) is useful as anti-ulcer agent and very unstable in acid is provided. The microgranule uses alkali compound as stabilizer and water soluble high polymer as binder to maximize stability thereof. CONSTITUTION: A microgranule contains 5-pirrolyl-2-pyridylmethylsulfinylbenzimidazole derivative as effective component, 0.2-7.0 times of alkali compound as stabilizer based on molar amount of the effective component and 0.1-50 wt.% of water soluble high polymer as binder based on the total weight of microgranule. The water soluble high polymer can be hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, sodium alginate, alginic acid etc.. The alkali compound can be magnesium oxide, sodium phosphate dibasic, sodium phosphate monobasic, magnesium hydroxide, aluminium hydroxide, aluminium carbonate etc.. The microgranule having maximized stability enables the effective component to be stored at room temperature while transporting for industrial use.
Abstract translation: 目的：含有稳定的5-吡咯基-2-吡啶基甲基亚磺酰基苯并咪唑衍生物（式1）的微粒可用作抗溃疡剂，并且在酸中非常不稳定。 微粒使用碱性化合物作为稳定剂和水溶性高分子作为粘合剂使其稳定性最大化。 构成：微粒含有5-吡咯基-2-吡啶基甲基亚磺酰基苯并咪唑衍生物作为有效成分，基于有效成分摩尔量的0.2-7.0倍碱稳定剂和0.1-50重量％作为粘合剂的水溶性高分子作为粘合剂 微粒的总重量。 水溶性高分子可以是羟甲基纤维素，羟乙基纤维素，羟丙基纤维素，羟丙基甲基纤维素，海藻酸钠，藻酸等。碱性化合物可以是氧化镁，磷酸氢二钠，磷酸二氢钠，氢氧化镁，氢氧化铝，碳酸铝等。 具有最大化稳定性的微粒使得有效成分能够在室温下储存，同时运输用于工业用途。
-
公开(公告)号：KR1020000020628A
公开(公告)日：2000-04-15
申请号：KR1019980039304
申请日：1998-09-22
Applicant: 일양약품주식회사
IPC: A61K31/44
CPC classification number: A61K9/2009 , A61K9/2866 , A61K9/2886 , A61K31/4439
Abstract: PURPOSE: An oral preparation of the 5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazole derivatives which treat ulcer is provided for improving the stability to acidic condition. CONSTITUTION: The oral preparation is prepared by mixing 1 mol of the5-pyrrolyl-2-pyridylmethylsulfinylbenzimidazole derivatives represented by the formula 1 with 0.2-7.0 mol of an alkali compound being a stabilizing agent; coating the mixture with a water-soluble polymer; and coating it with a coating agent for an intestine. The alkali compound is one or more compounds selected from magnesium oxide, sodium hydrogen phosphate, potassium hydrogen phosphate, magnesium hydroxide, magnesium carbonate, aluminum hydroxide, aluminum carbonate, calcium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium carbonate, potassium hydrogen carbonate, aluminum phosphate, calcium phosphate, sodium phosphate, potassium phosphate, aluminum citrate, calcium citrate, sodium citrate, potassium citrate, aluminum/magnesium compounds complex (Al2O3-6MgO-12H2O or MgO-Al2O3-2SiO2-nH2O), arginine, lysine and histidine. The water-soluble polymer is one or more compounds selected from hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose and sodium alginate, and used in amount of 0.5-50 wt% based on the total weight after the first coating.
Abstract translation: 目的：提供治疗溃疡的5-吡咯基-2-吡啶基甲基亚磺酰基苯并咪唑衍生物的口服制剂，用于提高酸性条件的稳定性。 构成：通过将1摩尔式1表示的5-吡咯基-2-吡啶基甲基亚磺酰基苯并咪唑衍生物与0.2-7.0摩尔作为稳定剂的碱性化合物混合来制备口服制剂; 用水溶性聚合物涂覆混合物; 并用肠包衣剂包衣。 碱化合物是选自氧化镁，磷酸氢钠，磷酸氢钾，氢氧化镁，碳酸镁，氢氧化铝，碳酸铝，碳酸钙，碳酸钠，碳酸氢钠，碳酸钾，碳酸氢钾， 磷酸铝，磷酸钙，磷酸钠，磷酸钾，柠檬酸铝，柠檬酸钙，柠檬酸钠，柠檬酸钾，铝/镁化合物络合物（Al2O3-6MgO-12H2O或MgO-Al2O3-2SiO2-nH2O），精氨酸，赖氨酸和组氨酸 。 水溶性聚合物是一种或多种选自羟甲基纤维素，羟乙基纤维素，羟丙基甲基纤维素和藻酸钠的化合物，其用量为第一次涂覆后的总重量的0.5-50wt％。
-
-
-
-
-
-
Search Results
7
records
(took 0.017 seconds)
